
(1) Disturbing reports of cancers linked to topical application of tacrolimus or pimecrolimus have been published. Some involved children. Animal studies had already shown a dose-dependent increase in the incidence of lymphoma in mice and monkeys. (2) In practice, it is better to avoid topical application of these immunosuppressants, which have a negative risk-benefit balance.

